HOME Research Insight Major players in the Isothermal Nucleic Acid Amplification Technologies market considered agreements, partnerships and collaboration as the key strategy to expand their footprint in the market



Major players in the Isothermal Nucleic Acid Amplification Technologies market considered agreements, partnerships and collaboration as the key strategy to expand their footprint in the market


The key players in Isothermal Nucleic Acid Amplification Technologies (INAAT) market include bioMerieux (France), Eiken Chemical Co. Ltd. (Japan), NuGEN (U.S.), Meridian Bioscience, Inc.(U.S.), Lucigen (U.S.), QIAGEN (The Netherlands), Alere, Inc.(U.S.), Becton, Dickinson and Company (U.S.), New England Biolabs(U.K.), Biohelix (U.S.), Ustar Biotechnologies (China), and Novartis Diagnostics (Spain).

Novel technology adoption and up-gradation of existing portfolio were found to be major focus of leading companies in the global INAAT market. Market players have adopted various strategies to strengthen their presence with robust portfolio and geographical reach. In depth research in the Isothermal Nucleic Acid Amplification Technologies market has identified that agreements, partnerships and collaboration is the key strategy followed by major players to enhance their existing portfolio Major players such as Biomerieux (France), Becton, Dickinson and Company (BD) (U.S.), QIAGEN (The Netherlands), and NuGEN (U.S.) adopted this strategies to retain their leading position in the market. For instance, QIAGEN partnered with Exosome Diagnostic, Inc. in 2014 to develop non-invasive molecular diagnostics for the detection of genetic mutations in lung cancer patients.

In addition to this, some companies also focused on new product launches to enhance their product offerings. Notable players, that introduced novel technologies in the market, include Becton, Dickinson and Company (U.S.), Meridian Bioscience, Inc. (U.S.), QIAGEN (The Netherlands), and Lucigen (U.S.). In 2014, Becton, Dickinson and Company received CE/IVD marking for the BD Onclarity HPV Assay on the new BD Viper LT System to provide physicians the access to broader high-risk HPV genotype information. On the other hand, mergers and acquisitions was followed by a few market players. The major players involved in mergers and acquisitions activities include bioMerieux(France), Novartis Diagnostics (Spain), Biohelix (U.S.), QIAGEN (The Netherlands), Eiken Chemical Co. Ltd. (Japan), and New England Biolabs (U.K.).

Besides such inorganic growth strategies, companies also focused on securing significant capital investment to develop novel technologies using in-house capabilities. In 2013, eight investments were found to be significant in the global INAAT market; Catapult Venture Managers Ltd. and Tate & Lyle Ventures’ investment amounted $963,690 to Lumora Ltd. for developing advanced isothermal technology was the highest amongst all investments. In this dynamic scenario, patent proprietorship plays a pivotal role in establishing market dominance in the global INAAT market. For instance, bioMerieux has patented nucleic acid sequence based amplification (NASBA) technology; whereas, BioHelix (Quidel) adopted helicase dependent amplification (HDA) technology for molecular testing.

Related Reports:

Isothermal Nucleic Acid Amplification Technology (INAAT) Market by Application (Infectious Diseases, Blood Screening, Research), Products (Instruments, Reagents), End-User (Hospital, Reference Laboratories, Other) - Global Forecast to 2018

Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports